INTRODUCTION
Diabetes is a serious public health problem [1] [2] [3] . Yang et al has shown that in China, agestandardized prevalence of total diabetes (which include both previously diagnosed diabetes and previously undiagnosed diabetes) and prediabetes was 9.7 % (10.6 % among men and 8.8 % among women) and 15.5 % (16.1 % among men and 14.9 % among women), respectively, accounting for 92.4 million adults with diabetes (50.2 million men and 42.2 million women) and 148.2 million adults with prediabetes (76.1 million men and 72.1 million women) [4] .
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of drugs for the management of type 2 diabetes [5] . Inhibitors stimulate insulin secretion in a glucose-dependent manner, DPP-4 inhibitors present lower risks on hypoglycemia and may not lead to weight gain, also protect pancreatic beta cells. The up-regulation of gastric inhibitory polypeptide and pituitary adenylate cyclase activating polypeptide by DPP-4 inhibitor also result in blood glucose reduction [6, 7] . Clinical data indicate that treatment with DPP-4 inhibitors, in combination with other hypoglycemic drugs result in significantly improved glycemic control compared with DPP-4 inhibitor or metformin alone in patients with type 2 diabetes mellitus (T2DM) [8, 9] .
Retagliptin is a novel DPP-4 inhibitor. Its chemical structure was shown in the Figure 1 . Retagliptin has entered into clinical trial phase II in USA under approval by FDA. Our previous clinical studies of retagliptin in healthy volunteers showed a dose-dependent manner in DPP-4 inhibition present a good correlation between DPP-4 inhibition ratio and plasma concentration of retagliptin acid. The objective of the present study was to establish a method to evaluate the safety and pharmacokinetic interaction of synergism of retagliptin combined with metformin in healthy subjects, and to support a clinical protocol of retagliptin combined with metformin. 
METHODS

Subjects
The experiment was designed for single center, randomized, opened and three period crossover. The study was carried out in the national clinical drug trial institution of the General Hospital of Chengdu Military Region. The study was approved and registered by the hospital's Ethics Committee in July in 2011 (approval no. CDJ-11-07-03). All subjects signed written informed consent form and all aspects of the work were undertaken according to the provisions of the Declaration of Helsinki.
Main inclusion criteria include that participants should be healthy male and female; female should not be pregnant using acceptable method contraception; and subjects aged 18 -45 years, with a body mass index of 19 -24 were eligible for inclusion. Routine inspection of their medical history, vital signs, safety laboratory tests and electrocardiograms (ECGs) were conducted to determine eligibility for the studies.
The main exclusion criteria include history of allergies or hypersensitivity to the study drugs or their excipients; abuse of drugs or alcohol within 6 months prior to enrollment; use of prescription medications or herbal preparations within 4 weeks prior to enrollment; and use of over-thecounter medication or vitamins within 2 weeks prior to enrollment. Volunteers with evidence of organ dysfunction or any clinically significant deviations from normal in physical examinations, vital signs, electrocardiogram (ECG), or clinical laboratory determinations which may affect drug pharmacokinetics or compliance were also excluded.
Study design
The study was an open-label, randomized, 3-period, 3-treatment (A, B, C), crossover study in healthy subjects. The dosage of retagliptin used in this study was determined by previous trials of single and multiple-dose administration of retagliptin alone. a total of 15 eligible subjects were randomized to 1 of 3 possible treatment sequences (ABC, BCA, CAB) and to receive the following 3 treatment: treatment A, retagliptin (100 mg q.d.); treatment B, metformin (1500 mg q.d.); treatment C, retagliptin (100 mg q.d.) + metformin (1500 mg q.d.). A 5-day washout period was employed between 5-day treatments periods, after which subjects were crossed over to receive the next treatment specified in their treatment sequence. Blood samples were collected at 2, 3, 4, 5 day following administration.
To confirm steady-state concentration following co-administration, blood samples prior to administration on 2nd, 3rd and 4th day were analyzed. Figure 2 shows the study design.
Subjects were admitted to a clinical unit one day prior to each study phase with fasting overnight for at least 8 h. Then they received medicine with plain water (retagliptin 100mg or metformin 1500 mg or retagliptin 100 mg + metfromin 1500 mg) after taking baseline examination in the next morning. Subjects were administered medicine before meal every day. Standard meals were served during each treatment periods. Drugs were administered after a 4 -h fast and subjects should leave clinical unit until all the plasma sample collection were finished in the 5 days of each treatment phase. 
Safety assessment
Safety assessment was based on the characteristics, frequency and severity of adverse events; signs and symptoms of hypoglycemia; physical examination and vital signs; routine safety laboratory tests; urinalysis; hematology; biochemistry and a 12-lead ECG.
The subjects underwent safety examinations before the first dosing, 4 h after fifth dosing in each phase, and after the last blood collection respectively. If abnormal signs were detected in the third phase before the end of the trials, following up visit is necessary until the patients return to normal condition. During the whole clinical trials the subjects should keep bland diet, avoid strenuous exercises and long period of bed rest. They were forbiddance of juice, tea, and coffee, alcohol which contains caffeine or alcohol. Cigarettes or anything that can affect the pharmacokinetics or safety evaluation were forbidden.
Pharmacokinetic analysis and bioanalysis
Blood samples for determination of drug concentration and pharmacokinetics were collected at specific time points, depending on the characteristics of each drug.
Plasma concentrations of retagliptin, retagliptin acid (a main metabolite of retagliptin), metformin were determined by separated, validated liquid chromatography-tandem mass spectrometry methods [10, 11] . The linearity ranges of quantitative detection were 2-200 ng/mL for retagliptin; 5 -1000 ng/mL for retagliptin acid; 50 -2000 ng/mL for metformin. The lower limit of quantitation was 2 ng/mL for retagliptin, 5 ng/mL for retagliptin acid and 50 ng/mL for metformin. The difference between variability for the quality controls of retagliptin was < 8.4 and < 7.8 %, respectively. The difference between variability for the quality controls of retagliptin acid was < 10.8 and < 9.8 %, respectively. The difference between variability for the quality controls of metformin was < 3.8 and < 5.2 %, respectively.
Data analysis
Descriptive statistics including mean, standard deviation, relative standard deviation (RSD), minimum and maximum (range), median and % CV for continuous variables; and also number, frequency and percentage were conducted. Pharmacokinetic parameters were calculated by non-compartmental methods using WinNonlin software version 6.1 (Pharsight Corp, Mountain View, CA, USA) for plasma.
Pharmacokinetics interactions were assessed by bioequivalency assay. Absence of statistically significant interaction between retagliptin and metformin was confirmed if the 90 % confidence interval (CI) of both glucose-lowering drugs' AUC inf and C max of the geometric mean ratios (GMRs) of retagliptin + metformin versus retagliptin alone, fell within the pre-specified interval of 80 -125 %. Table 1 showed the descriptive statistics of the pharmacokinetic parameters for retagliptin with or without metformin. Table 2 shows the GMRs and 90 % CI of AUC inf and C max for retagliptin with or without metformin.
RESULTS
Pharmacokinetics
As can be seen from Tables 1 and 2 , when retagliptin was co-administered with metformin, the AUC inf and C max of retagliptin were 16.49 and 25.88 % higher than retagliptin alone respectively, and the GMRs and 90 % CI for the ratios of AUC inf and C max were beyond the upper limit of the interval (80 -125 %).
When retagliptin was co-administered with metformin, the C max of retagliptin acid increased, and the GMRs and 90 % CI for the ratios of AUC inf and C max fell within the predefined interval (80 -125 %).
When retagliptin was co-administered with metformin, the AUC inf of metformin increased 21.77 %, and the GMRs and 90 % CI for the ratios of AUC inf and C max fell within the predefined interval (80 % -125 %). The time profile of the drugs in plasma concentration is displayed in Figure 3 .
Safety and tolerability
During the clinical trials, all subjects were well monitored by researchers.
There were no serious adverse events in the whole trials. The adverse events mainly were gastro-intestinal tract response including nausea, anorexia, sickness and diarrhea. Central nervous system symptoms including dizziness and sleepiness appeared in few subjects. The AE incidence rate of metformin treatment alone was much higher than retagliptin treatment alone. The AE incidence rate and type of combination treatment was similar with retagliptin or metformin alone. One female subject from the metformin alone group took place moderate diarrhea. The symptoms continued 5 days until the drug withdrawal. The rest of the adverse events were all mild situations. The subjects alleviate by themselves without treatment. All treatments in the trials were well tolerated. The most frequently reported AEs were summarized in Table 3 .
No laboratory adverse conditions, including hypoglycemia, or treatment-related clinically significant deviations in physical examinations and ECG parameters occurred during the study. [14, 15] . Retagliptin has more effective than sitagliptin in vitro inhibition activity in several diabetes animal models. This will need to be further proved eventually in human patients with diabetes mellitus.
In an attempt to clarify the safety and potential pharmacokinetic interaction between retagliptin, a selective inhibitor of DPP-4, and metformin, we studied their PK interaction in healthy subjects. With this approach it was possible to prove that the combination increased the system exposure of both metformin and retagliptin. Compared with using retagliptin alone, the C max increased by 25.88 % in retagliptin combined with metformin hydrochloride sustained-release tablets; the AUC increased by 16.49 %. The 90 % confidence interval of AUC ratio of retagliptin acid combination with metformin/retagliptin acid alone was 80 -125 %, the combination use of drug increased C max slightly compared with using drug alone, So dose adjustment is needed when retagliptin combining used with metformin in actual situation, and should be adjusted according to related clinical curative effect analysis and judgment.
Our results showed that the combination increased the system exposure of both metformin and retagliptin, which may be related to the kidney excretion style of the both drugs. It was reported that metformin itself was able to inhibit the activity of DPP-4 [16] .
CONCLUSION
The combination of retagliptin and metformin leads not only to significantly higher C max and AUC inf of retagliptin but also higher AUC inf of metformin. However, there is no pharmacokinetic interaction between metformin and sitagliptin [17] . The dosage of metformin between 1000 mg and 2500 mg produces similar incidence of gastrointestinal side effects with no obvious dose -effect relationship. No dose-adjustments are likely to be required when retagliptin is given in combination with metformin.
